Researchers have found statistically significant links between a gene tied to schizophrenia risk and poorer cognitive performance in a large population sample, adding new evidence that genetic variation can shape how well people think, remember, and make decisions. The gene in question, complement component 4A (C4A), was already known to increase schizophrenia susceptibility. Now, a peer-reviewed study using UK Biobank data shows its predicted expression in the brain correlates with measurable deficits in healthy individuals, not just those diagnosed with the disorder.
How C4A Became a Prime Suspect in Schizophrenia
The story of C4A begins with a 2016 study in which investigators examined structural variation at the C4 locus on chromosome 6 and showed that the number of C4A gene copies predicts how much protein the brain produces, with higher predicted expression linked to elevated risk of schizophrenia. That work also proposed a biological mechanism: C4A protein helps tag synapses for elimination by immune cells in a process called synaptic pruning. When this pruning becomes too aggressive, particularly during adolescence and early adulthood, it may remove neural connections that the brain still needs for normal information processing.
This hypothesis stood out because schizophrenia has long resisted simple genetic explanations. Large-scale analyses have shown that the disorder arises from many common variants of small effect rather than a few mutations with large impacts, and that these variants influence multiple biological pathways and environmental interactions. In such a polygenic context, isolating any single gene’s contribution to behavior is difficult, which is why evidence connecting C4A to both brain biology and clinical risk drew so much attention.
More recent work has expanded this picture. Using postmortem tissue and genomic data, researchers supported by the National Institute of Mental Health have mapped how schizophrenia-associated variants cluster in brain regions and cell types involved in synaptic function and dopaminergic signaling, suggesting that many risk loci, including C4A, may converge on shared neural circuits. That convergence raises the possibility that different genes could produce overlapping cognitive and decision-making problems through distinct but intersecting mechanisms.
UK Biobank Data Ties C4A to Cognitive Deficits
A study published in Psychological Medicine took the next logical step: testing whether the same C4A variation that raises schizophrenia risk also affects cognition in the general population. Using genetic and phenotypic data from UK Biobank participants, the researchers inferred each person’s brain C4A expression from their structural variants at the C4 locus and then compared those predictions with performance on standardized tasks. They found robust associations between higher predicted C4A levels and poorer scores on measures of episodic memory, processing speed, and executive function.
Importantly, these associations emerged in individuals without diagnosed psychotic disorders, indicating that C4A’s cognitive impact is not confined to clinical schizophrenia. Instead, the gene appears to shape variation in thinking skills across the broader population. The same analysis also examined brain imaging markers, including cortical thickness and surface area in regions implicated in working memory and planning, and reported subtle structural differences consistent with the idea that excess complement activity may alter how key networks develop.
While the effect sizes were modest, they were statistically significant at the population level. In practical terms, that means C4A is unlikely to determine any one person’s cognitive fate, but across hundreds of thousands of people, those with genetically higher expression tended to perform slightly worse. For researchers, such patterns offer a window into how molecular pathways involved in synaptic pruning could influence everyday abilities like learning new information or making complex choices.
Decision-Making Deficits in Schizophrenia Are Well Documented
Separate lines of research have established that people with schizophrenia often struggle with reward-based decision-making. One influential meta-analysis and computational modeling project combined data from multiple studies using the Iowa Gambling Task, a card game in which participants must learn to favor long-term gains over tempting short-term rewards. Across pooled samples of hundreds of individuals with schizophrenia and healthy controls, patients consistently showed poorer learning from feedback and a tendency to keep choosing disadvantageous decks.
These laboratory findings mirror real-world difficulties. Cognitive impairments, including problems with attention, working memory, and flexible decision-making, have been identified as some of the strongest predictors of functional outcomes. Longitudinal studies indicate that such deficits can limit a person’s ability to maintain employment, manage finances, and navigate social relationships. A review of clinical criteria has even argued that cognitive disturbances are central to the core definition of schizophrenia, often proving more disabling than hallucinations or delusions.
Against this backdrop, genetic findings around C4A acquire added significance. If a gene implicated in synaptic pruning subtly shifts cognitive performance in the general population, and more dramatically in those with schizophrenia, it could help explain why decision-making problems are so common and why they often persist even when psychotic symptoms are controlled with medication.
COMT and the Dopamine Connection
C4A is not the only schizophrenia-linked gene with documented effects on decision-making. The COMT gene encodes catechol-O-methyltransferase, an enzyme that helps break down dopamine in the prefrontal cortex. A functional polymorphism known as Val158Met alters the enzyme’s activity, with downstream consequences for dopamine signaling. Experimental work in healthy volunteers has shown that this variant modulates emotional choices on gambling tasks, with different genotypes displaying distinct patterns of risk-taking and sensitivity to losses.
A pharmacogenetic study extended these findings by combining genotype data with drug manipulation. When participants received a COMT inhibitor designed to boost prefrontal dopamine, the impact on monetary decision-making depended on their Val158Met status. For one genotype, inhibition improved performance on reward-learning tasks, while for the other, it led to worsening outcomes. The authors concluded that COMT variation can reverse the direction of cognitive drug effects, underscoring the importance of personalized approaches in neuropsychiatric treatment development.
Although no published research has yet directly tested interactions between C4A-driven synaptic pruning and COMT-mediated dopamine regulation, both pathways converge on prefrontal cortex function. It is plausible that individuals carrying high-risk configurations in both systems could experience compounded impairments in working memory and flexible decision-making, while others with more protective profiles remain relatively resilient despite similar environmental exposures.
What Stands Between These Findings and New Treatments
The National Institute of Mental Health has emphasized that common schizophrenia risk variants appear to cluster in networks related to synaptic organization and dopaminergic signaling, raising hopes that genetic discoveries could eventually guide targeted interventions. Yet several obstacles stand between current findings and new therapies. First, the effect of any single common variant, including C4A or COMT Val158Met, is small, which limits their usefulness as standalone predictive tools. Second, most association studies are observational, making it difficult to infer causality or to know whether modifying a given pathway would meaningfully improve cognition.
Translating genetic insights into drugs is further complicated by individual variability. As the COMT inhibitor study illustrates, the same pharmacological agent can help one subgroup while harming another, depending on genotype. For C4A, intervening directly in the complement system carries additional risks because those proteins are crucial for immune defense. Blunting their activity to protect synapses could inadvertently increase susceptibility to infections or autoimmune problems, especially if treatments were given during sensitive developmental windows.
To navigate these challenges, researchers are turning to large-scale, genotype-informed clinical studies. Registries of ongoing and completed human experiments, such as public trial databases, now include numerous efforts aimed at improving cognition in schizophrenia, from cognitive training protocols to drugs that modulate glutamate or dopamine. As more of these studies incorporate genomic data, it may become possible to identify which combinations of variants predict benefit, or risk, from particular interventions.
In the meantime, the emerging picture from C4A, COMT, and related work underscores the need to treat cognitive and decision-making impairments as central therapeutic targets, rather than secondary concerns. Even modest genetic influences on thinking skills can have large cumulative effects at the population level, shaping educational attainment, occupational success, and quality of life. By integrating molecular genetics, brain imaging, behavioral testing, and carefully designed trials, scientists hope to move from statistical associations toward mechanisms that can be safely and effectively manipulated.
The latest C4A findings do not offer a ready-made treatment, but they do tighten the link between a specific genetic pathway and the everyday mental abilities that matter most for independence and well-being. As researchers continue to map how risk variants alter brain circuits and behavior, the long-term goal is to develop interventions that preserve or restore cognitive function, ideally tailored to each person’s unique genetic profile.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
